Catalog No.
DHC33101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
EDF, Erythroid differentiation protein, Activin beta-A chain, INHBA, Inhibin beta A chain
Concentration
1.02 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08476
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN2477, CAS: 2097125-54-5
Clone ID
Garetosmab
Antibodies to watch in 2021, PMID: 33459118
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study, PMID: 32557665
A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma., PMID:40033065
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation., PMID:39481534
Comparison of PET/CT versus CT only in the assessment of new heterotopic ossification bone lesions in patients with fibrodysplasia ossificans progressiva., PMID:39395655
INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling., PMID:39223366
Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial., PMID:39216107
How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva., PMID:38254701
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial., PMID:37770652
Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 Trial., PMID:37694449
Retinoid Agonists in the Targeting of Heterotopic Ossification., PMID:34831466
Antibodies to watch in 2021., PMID:33459118
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study., PMID:32557665
For research use only. Not for human or drug use.
